Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLEC5A siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CLEC5A siRNA is a research-grade small interfering RNA (siRNA) designed to silence the expression of the C-type lectin domain family 5 member A (CLEC5A) gene, also known as Myeloid DAP12-associating lectin 1 (MDL-1). By triggering the degradation of CLEC5A mRNA, this RNA interference (RNAi) agent knocks down the CLEC5A receptor on myeloid cells, particularly macrophages. CLEC5A is a critical mediator of the inflammatory response; its activation by viruses like dengue and Japanese encephalitis virus (JEV) triggers proinflammatory cytokine release. In oncology, CLEC5A has been identified as a regulator of tumor-associated macrophage (TAM) polarization and immunosuppression in the glioblastoma (GBM) microenvironment. While explored in preclinical models for viral infections and glioblastoma, it currently exists primarily as a research tool rather than a clinical-stage therapeutic.
- Other names
- CLEC5A small interfering RNACLEC-5A small interfering RNACLEC 5A small interfering RNAMDL-1 siRNAMDL1 siRNAMDL 1 siRNA
Beyond the preview
Go deeper on CLEC5A siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLEC5A siRNA.